公开(公告)号：US20230286904A1

公开(公告)日：2023-09-14

申请号：US18013431

申请日：2021-07-02

Applicant: BRIDGENE BIOSCIENCES, INC.

Inventor： Chao ZHANG ,  Michael J. BISHOP ,  Hang CHEN ,  Ping CAO

IPC: C07C233/25 ,  A61K45/06 ,  C07C233/27 ,  C07C251/42 ,  C07D333/32 ,  C07D333/36 ,  C07D213/643 ,  C07D311/68 ,  C07D215/38 ,  C07D213/64 ,  C07D261/08 ,  C07D231/12 ,  C07D231/54 ,  C07D261/20 ,  C07D271/06 ,  C07D249/06 ,  C07D309/14 ,  C07D261/12 ,  C07D217/24 ,  C07D213/40 ,  C07D237/08 ,  C07D275/02 ,  C07D205/04 ,  C07C233/23

CPC classification number: C07C233/25 ,  A61K45/06 ,  C07C233/23 ,  C07C233/27 ,  C07C251/42 ,  C07D205/04 ,  C07D213/40 ,  C07D213/64 ,  C07D213/643 ,  C07D215/38 ,  C07D217/24 ,  C07D231/12 ,  C07D231/54 ,  C07D237/08 ,  C07D249/06 ,  C07D261/08 ,  C07D261/12 ,  C07D261/20 ,  C07D271/06 ,  C07D275/02 ,  C07D309/14 ,  C07D311/68 ,  C07D333/32 ,  C07D333/36 ,  C07C2602/08 ,  C07C2602/10 ,  C07C2602/50

Abstract: Disclosed herein are synthesis and use of covalent inhibitors selective for Transcriptional Enhancer Factor TEF-1 (TEAD1), which can be used for treatment of cancers such as glioblastoma, gastric cancer, colorectal cancer, pancreatic ductal adenocarcinoma (PDAC), and malignant pleural mesothelioma (MPM). Further disclosed herein are pharmaceutical compositions including the TEAD1 inhibitor and methods of treating cancers using the same.

公开(公告)号：US20220288069A1

公开(公告)日：2022-09-15

申请号：US17626486

申请日：2020-07-17

Applicant: BridGene Biosciences, Inc.

Inventor： Chao Zhang ,  Ping Cao ,  Michael J. Bishop

IPC: A61K31/506 ,  C07D403/12 ,  C07D413/14 ,  C07D403/14 ,  C07D417/12 ,  C07D417/14 ,  C07D403/06 ,  C07D209/34 ,  A61K45/06 ,  A61K31/5377 ,  A61K31/4439 ,  A61K31/404

Abstract: The present disclosure provides compounds and compositions thereof which are useful as inhibitors of tyrosine kinase and which exhibit desirable characteristics for the same. Further disclosed herein are methods of treating cancer using these tyrosine kinase inhibitor compounds.

公开(公告)号：US20220276253A1

公开(公告)日：2022-09-01

申请号：US17630815

申请日：2020-08-04

Applicant: BridGene Biosciences, Inc.

Inventor： Ping Cao ,  Yuan Yuan ,  Chao Zhang

IPC: G01N33/58 ,  G01N33/68

Abstract: The present disclosure provides a profiling method based on comparative mass spectrometry analysis for identifying and quantifying the covalent interactions of electrophilic compounds with diverse proteins in complex proteomes, as well as compositions for performing the method.

公开(公告)号：US20220218703A1

公开(公告)日：2022-07-14

申请号：US17430621

申请日：2020-02-14

Applicant: BridGene Biosciences, Inc.

Inventor： Ping Cao ,  Chao Zhang ,  Michael J. Bishop

IPC: A61K31/506 ,  A61K45/06 ,  C07D405/14 ,  C07D401/04 ,  C07D401/14

Abstract: The disclosure provides novel FGFR inhibitors based on the pyridinylpyrimidine. The disclosure includes inhibitors with broad inhibitory activity against all FGFR isoforms, and inhibitors with selective inhibition against FGFR4. These novel pyridinylpyrimidine-based FGFR inhibitors, or their derivatives, have strong potential to be used to treat cancer.